Renal Cancer - Results from #2460

Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity. October 13, 2020

PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma. October 12, 2020

Cytomorphologic analysis of clear cell papillary renal cell carcinoma: Distinguishing diagnostic features. October 12, 2020

SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients. October 12, 2020

Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. October 9, 2020

Cell Polarity Protein Pals1-Associated Tight Junction Expression Is a Favorable Prognostic Marker in Clear Cell Renal Cell Carcinoma. October 9, 2020

Interobserver Variability in Assessment of Renal Mass Biopsies. October 9, 2020

Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. October 8, 2020

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). October 8, 2020

Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including its Variant Morphologies. October 8, 2020

Targeting the HIF2-VEGF axis in renal cell carcinoma. October 8, 2020

From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer. October 7, 2020

Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. October 7, 2020

Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. October 7, 2020

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. October 6, 2020

TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma. October 6, 2020

The Role of Metabolic Factors in Renal Cancers. October 6, 2020

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. October 5, 2020

Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. October 5, 2020

Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. October 5, 2020

Page 124 of 456